Location History:
- North Brunswick, NJ (US) (1993)
- Dayton, NJ (US) (1997 - 2016)
- Stockbridge, GA (US) (2015 - 2016)
Company Filing History:
21 out of 108 
12 out of 59 
10 out of 142 
Years Active: 1993-2016
Areas of Expertise:
Title: Innovator Spotlight: Kondareddiar Ramalingam
Introduction: Kondareddiar Ramalingam is a noteworthy inventor located in Dayton, NJ, with an impressive portfolio of 47 patents. His contributions to the field of biotechnology focus on essential therapeutic areas such as angiogenesis, which plays a critical role in various diseases, including cancer.
Latest Patents: Among his latest innovations are the patents for KDR and VEGF/KDR binding peptides and their uses in diagnosis and therapy. These inventions present polypeptides, peptide dimers, and multimeric complexes that include at least one binding moiety for the KDR or VEGF/KDR complex. They possess significant applications in treating, detecting, isolating, or localizing angiogenesis. Particularly noteworthy are the synthetic, isolated polypeptides that bind to the KDR or VEGF/KDR complex with high affinity and the multimeric constructs that incorporate these polypeptides, including their use as contrast agents in medical imaging. Additionally, these patents provide methods for evaluating the effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation.
Career Highlights: Throughout his career, Kondareddiar has made significant strides in the biomedical field. He has worked with reputable companies such as Bracco International Bv and Bracco Suisse Sa, which have allowed him to integrate his innovative thinking with practical applications in healthcare technology.
Collaborations: Kondareddiar Ramalingam has collaborated with esteemed professionals such as Karen E. Linder and Adrian D. Nunn. These collaborations have further propelled his research and development initiatives, leading to the advancement of his patented technologies.
Conclusion: Kondareddiar Ramalingam stands out as a prolific inventor whose work in the development of KDR and VEGF/KDR binding peptides has the potential to facilitate remarkable advancements in medical diagnosis and therapy. His expertise and dedication to innovation contribute significantly to the ongoing fight against diseases related to angiogenesis.